Chase Pharmaceuticals
Alzheimer’s therapeutics (sold to Allergan for $1B in 2016)

New Rhein Concludes Successful Investment in Chase (2016)

Chase Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders. Chase’s development program, if successful, will profoundly improve the symptomatic treatment of Alzheimer’s disease. The company was co-founded by Thomas Chase, MD, the former Scientific Director and head of the Experimental Therapeutics Branch for the National Institute of Neurological Disorders and Stroke and Kathleen Clarence-Smith, MD, PhD, the former head of CNS development at each of Sanofi, Hoffmann-La Roche and Otsuka.

Chase is led by its chief executive officer and president, Douglas Ingram, formerly the president of Allergan, Inc.  Chase’s Board is headed by its Chair, Greg Parekh, founding partner of New Rhein Healthcare Investors, LLC, and formerly worldwide head of M&A at Novartis.

Chase has closed over $24 million in funding, with approximately $22 million through a Series B financing led by New Rhein Healthcare Investors, LLC and including, among others, Edmond de Rothschild Investment Partners, Cipla Ventures and Brain Trust Accelerator Fund.

Allergan Acquires Chase

Allergan Could Pay $1B for Chase